Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2815-2824

  Shin, Incheol ^a,e   Edl, Jeniffer ^c   Biswas, Swati ^a   Lin, P Charles ^a,b   Mernaugh, Raymond ^a,c   Arteaga, Carlos L ^a,b,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Vanderbilt Ingram Compreh Cancer C   (United States)

^d Vanderbilt Ingram Compreh Cancer C   (United States)

^e Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AKT SINGLE CHAIN VARIABLE ANTIBODY; CARRIER PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN KINASE B BETA; RECOMBINANT ENZYME; SERINE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY LIBRARY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE EXPRESSION; HUMAN; HUMAN CELL; MICHAELIS CONSTANT; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTIBODIES; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; GLUTATHIONE TRANSFERASE; HUMANS; MICE; PEPTIDE LIBRARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS;

EID: 16844381988     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2898     Document Type: Article

References (59)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
2. Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 2001;19:833-41.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
5. Clark, M. Antibody humanization: a case of the "Emperor's new clothes"? Immunol Today 2000;21:397-402.
6. Fishwild DM, O'Donnell SL, Bengoechea T, et al. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996;14:845-51.
7. Hudson, PJ. Recombinant antibody fragments. Curr Opin Biotechnol 1998;9:395-402.
8. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-4.
9. Mernaugh R, Mernaugh G. An overview of phage-displayed recombinant antibodies. In: Singh RP, Sing US, editors. Molecular methods in plant pathology. Boca Raton (FL): CRC Press; 1995. p. 359-65.
10. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
11. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-64.
12. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-9.
13. Kops GJ, Burgering BM. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 1999;77:656-65.
14. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21.
15. Nicholson KM, Andersen NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95.
16. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 1987;84:5034-7.
17. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5.
18. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998;21:81-6.
19. Vlahos CJ, Matter WF, Brown RF, et al. Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase. J Immunol 1995;154:2413-22.
20. Nakamura I, Takahashi N, Sasaki T, et al. Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. FEBS Lett 1995;361:79-84.
21. Franke TF, Yang SI, Chan TO. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-36.
22. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem 1994;269:3568-73.
23. Rojas M, Donahue JP, Tan Z, Lin YZ. Genetic engineering of proteins with cell membrane permeability. Nat Biotechnol 1998;16:370-5.
24. Delli Bovi P, Curatola AM, Kern FG, Greco A, Ittmann M, Basilico C. An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell 1987;50:729-37.
25. Muraoka-Cook RS, Kurokawa H, Koh Y, et al. Conditional overexpression of active transforming growth factor β1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 2004;64:9002-11.
26. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
27. Lin PN, Shan S, Dewhirst M, Rao P, Peters KG. Inhibition of tumor growth by targeting tumor endothelium using a soluble form of the Tie-2/Tek receptor tyrosine kinase. J Clin Invest 1997;100:2072-8.
28. Webster MA, Hutchinson JN, Rauh MJ, et al. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 1998;18:2344-59.
29. Casamayor A, Morrice NA, Alessi DR. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 1999;342:287-92.
30. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.
31. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51.
32. Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bβ. J Biol Chem 1997;272:30491-7.
33. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A 1997;94:3627-32.
34. Hass-Kogan D, Shalev N, Wong, M, et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-8.
35. Nicholson DW, Ali A, Thornbeny NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
36. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1533-6.
37. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6.
38. Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001;91:22-6.
39. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
40. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-9.
41. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PI3KCA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
42. Bachman KE, Argani P, Samuels Y, et al. The PI3KCA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;8:772-5.
43. Chan TO, Tsichlis PN. PDK2: a complex tail in one Akt. Sci STKE, 2001;66:1-5.
44. Balendran A, Casamayor A, Deak M, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999;9:393-404.
45. Persad S, Attwell S, Gray V, et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001;276:27462-9.
46. Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 2003;278:22374-8.
47. Lynch DK, Ellis CA, Edwards PA, Hiles ID. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 1999;18:8024-32.
48. Hill MM, Feng J, Hemmings BA. Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 2002;12:1251-5.
49. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase CβII regulates Akt phosphorylation on Ser473 in a cell type- and stimulus-specific fashion. J Biol Chem 2004;279:47720-5.
50. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000;275:8271-4.
51. Li Q, Zhu GD. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem 2002;2:939-71.
52. Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the prosurvival serine/threonine kinase Akt. J Am Chem Soc 2003;125:1144-5.
53. Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol Cancer Ther 2003;2:389-99.
54. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;11:1093-103.
55. Yang L, Dan HC, Sun M, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004:64:4394-9.
56. Du C, Yao S, Rojas M, Lin YZ. Conformational and topological requirements of cell-permeable peptide function. J Pept Res 1998;51:235-43.
57. Lindgren M, Hallbrink M, Prochiantz A, Langel Ü. Cell-penetrating peptides. Trends Pharmacol Sci 2000;21:99-103.
58. Wang RF, Wang HY. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 2002;20:149-54.
59. Zhao Y, Lou D, Burkett J, Kohler H. Chemical engineering of cell penetrating antibodies. J Immunol Methods 2001;254:137-45.